Prof. Jason Davis is working alongside clinicians to introduce his biomarker assays into the clinic. Using a range of electroanalytical methods, together with electrode arrays and microfluidics, the platform has the potential to test for many types of cancers all at once, and at an earlier, pre-symptomatic stage.
Development fund awardee Gareth Bond is investigating how different types of genetic mutations cooperate to influence cancer risk, progression and response to therapy
Dr Francesco Boccellato is investigating the mechanisms behind the pre-cancerous condition known as atrophic gastritis. This may help to identify those who may have cancer, as well as find new ways to prevent cancer from progressing.
By analysing the metabolic molecules that tumour cells leave behind, Dr James Larkin is investigating the applications of metabolomics in the early detection of many cancers.
A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020.
Oxford cancer researchers have developed a new way of subtyping ovarian cancer that enables the accurate prediction of patient outcome and sheds light onto the role the immune system plays in ovarian cancer response to treatment.
Dr Philippa Matthews and colleagues review the associations between liver cancer risk and co-morbidities and other metabolic factors in individuals with chronic hepatitis B virus infection.
Dr Shivan Sivakumar and colleagues evaluate the current progress and future potential in using genetic and epigenetic methods for detecting pancreatic cancer DNA in the blood.
The SCALOP clinical trial team have uncovered a new therapeutic target for locally advanced pancreatic cancer. Read more about it and the next steps for the SCALOP-2 trial.
Nuffield Department of Population Health researchers are using the China Kadoorie Biobank to identify potential protein biomarkers in the blood that could be used to predict the presence or development of pancreatic cancer
The Song Lab recently developed an effective and accurate way of detecting cancer biomarkers in the blood. Now, they are looking at the application of TAPS technology in pancreatic cancer
Oxford spin-out Base Genomics is acquired by early cancer detection company Exact Sciences, for its ground-breaking TAPS technology, developed by Oxford cancer researchers
Researchers from the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) are utilising the China Kadoorie Biobank to better understand how breast cancer risk factors may differ between individuals from Western and Eastern populations
The Cancer Epidemiology Unit has been using the largest epidemiological data set of its kind to unlock the secrets of breast cancer, what can be done to prevent it, and which women are most likely to develop it
UK Research and Innovation provides additional funds for whole genome sequencing as part of the OxPLoreD programme of research into high-risk conditions for blood cancer
A pathway designed to investigate individuals with non-specific but concerning symptoms of cancer wins the BMJ Awards 2020 Cancer Care Team of the Year
A new study from S:CORT demonstrates an easy, cheap way to determine colorectal cancer molecular subtype using AI deep-learning digital pathology technology
Researchers in the Primary Care Epidemiology Group are joining two landmark projects to combine healthcare data and artificial intelligence to improve cancer diagnosis
![\"Polymer](\"https://www.cancer.ox.ac.uk/news/detecting-for-multiple-cancers-in-one-simple-test/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n